News & Publications

News Releases

April 22, 2025
FDA grants Breakthrough Therapy Designation for BrainChild Bio’s B7-H3 CAR T-cell therapy for incurable pediatric brain tumors

January 7, 2025
BrainChild Bio, Inc. to clinically advance BCB-276, an autologous B7-H3 targeting CAR T-cell therapy for incurable pediatric brain tumors

December 5, 2023
Seattle Children’s launches BrainChild Bio to accelerate CAR T-cell therapies for children with brain tumors

Publications

Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial
Nature Medicine
January 7, 2025

For press inquiries, please contact:
Barbara Yates
781-258-6153
[email protected]